Organon and Evvy team up to broaden access to single-dose BV treatment
Improving access to treatment for a condition affecting 21 million women in the U.S
Global healthcare company Organon and vaginal health brand Evvy have announced a new partnership to improve access to treatment for bacterial vaginosis (BV), a condition affecting an estimated 21 million women in the United States.
The agreement means that women diagnosed with bacterial vaginosis via Evvy’s at-home test may now obtain prescriptions of Organon’s XACIATO, a one-dose vaginal gel treatment through the Evvy platform. This potentially allows patients to get same-day treatment without needing to attend a clinic in person.
Common but misunderstood condition
The initiative marks a fresh approach to treating a common but frequently misunderstood condition. BV is the most prevalent vaginal infection among women aged 15 to 44 in the US, but its symptoms — often including odour and discharge — are routinely mistaken for yeast infections. If left untreated, BV can lead to more serious health complications, and disproportionately affects non-Hispanic Black and Mexican American women.
The move sees Organon, a healthcare company focused on women’s health, join forces with Evvy, a New York-based startup known for its work mapping the vaginal microbiome through at-home tests. The test uses metagenomic sequencing to identify over 700 microbes in a single swab, and has gained CLIA, CAP and CLEP certification — a first for a test of its kind.
“BV can be stigmatized, and many women prefer the privacy of home testing with quick access to treatment options,” said Elizabeth Stephens, Director of Women’s Health Strategy, Advocacy, and Partnerships at Organon.
“Through this strategic partnership with Evvy, we aim to create a patient-first experience that helps women more conveniently access the treatments she needs for her health.”
Single-use treatment
XACIATO is a prescription gel containing clindamycin phosphate, delivered in a single-use, pre-filled applicator. Women aged 12 and older who are diagnosed with BV by an Evvy-affiliated provider may be offered the treatment for same-day pickup at a local pharmacy.
Evvy says the integration of XACIATO into its platform is a direct response to the frustrations many women face navigating diagnosis and treatment for BV, a condition long underrepresented in innovation and research.
“We are excited to partner with Organon to expand access to XACIATO,” said Priyanka Jain, Co-Founder and CEO of Evvy.
“Despite the prevalence of BV, there has been a lack of innovation in BV treatment. We’re excited to offer our patients a new option designed with their experience in mind: a single dose treatment formulated with the goal of limiting leakage. By combining comprehensive testing, personalized care programs, and now, XACIATO, Evvy continues to lead the way in empowering women with data-driven, innovative healthcare.”
XACIATO’s arrival on the platform reflects a growing trend of companies offering targeted digital health services for women — particularly in areas long ignored by traditional healthcare systems. Evvy, which has so far served more than 50,000 women, also supports patients managing recurrent UTIs, yeast infections, fertility challenges and menopause.